NovaBay Pharmaceuticals Inc. (NBY) is primed for evolution with the beta value of 3.46

NovaBay Pharmaceuticals Inc. (NBY) is priced at $0.76 after the most recent trading session. At the very opening of the session, the stock price was $0.77 and reached a high price of $0.87, prior to closing the session it reached the value of $0.78. The stock touched a low price of $0.73.

Recently in News on September 8, 2020, NovaBay Announces that Avenova is Now Available with “Subscribe & Save”. Repays Secured Convertible Promissory Note. You can read further details here

NovaBay Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.9400 on 07/13/20, with the lowest value was $0.2400 for the same time period, recorded on 03/16/20.

NovaBay Pharmaceuticals Inc. (NBY) full year performance was 66.40%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, NovaBay Pharmaceuticals Inc. shares are logging -61.03% during the 52-week period from high price, and 215.04% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.24 and $1.94.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1649524 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the NovaBay Pharmaceuticals Inc. (NBY) recorded performance in the market was 18.14%, having the revenues showcasing -13.20% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 32.50M, as it employees total of 28 workers.

Analysts verdict on NovaBay Pharmaceuticals Inc. (NBY)

During the last month, 1 analysts gave the NovaBay Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.0200, with a change in the price was noted -0.2199. In a similar fashion, NovaBay Pharmaceuticals Inc. posted a movement of -22.53% for the period of last 100 days, recording 4,745,684 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for NBY is recording 0.50 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

NovaBay Pharmaceuticals Inc. (NBY): Technical Analysis

Raw Stochastic average of NovaBay Pharmaceuticals Inc. in the period of last 50 days is set at 6.78%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 11.33%. In the last 20 days, the company’s Stochastic %K was 11.67% and its Stochastic %D was recorded 11.72%.

Let’s take a glance in the erstwhile performances of NovaBay Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 18.14%. Additionally, trading for the stock in the period of the last six months notably improved by 121.67%, alongside a boost of 66.40% for the period of the last 12 months. The shares increased approximately by -1.82% in the 7-day charts and went up by -20.91% in the period of the last 30 days. Common stock shares were lifted by -13.20% during last recorded quarter.